Aminophyline

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aminophyline

Quick Facts

Property Description
Active ingredient Theophylline
Form Oral tablets, oral solution, rectal suppositories, intravenous injection
Pharmacological class Methylxanthine Derivative, Bronchodilator
General purpose Relieve reversible airflow obstruction and bronchospasm
Origin Synthetic compound (a chemical complex)

What Type of Drug is Aminophylline?

Aminophylline is a widely utilized prescription medicine classified as a bronchodilator belonging to the methylxanthine derivative pharmacological class. It is recognized as a single-ingredient agent primarily used to help manage respiratory issues characterized by constricted airways. As a pharmaceutical preparation, it is commonly produced in forms suitable for acute care, such as sterile solutions for intravenous injection, alongside more routine forms like oral tablets, oral liquids, and rectal suppositories.

The classification as a methylxanthine derivative positions it in a distinct chemical group characterized by its effect on smooth muscle tissue. The drug is distinctive among its immediate therapeutic class for its availability in a comprehensive range of forms, allowing for flexibility in its route of administration depending on the patient’s clinical need.


Composition: Aminophylline and Theophylline

Aminophylline is a synthetic compound that functions as the chemically modified, highly soluble salt or complex of its primary active therapeutic component, Theophylline. This specific chemical structure, which includes Ethylenediamine, serves to enhance the drug's solubility in water.

This modification is essential because pure Theophylline exhibits limited water solubility, which would prevent its effective formulation into certain critical delivery methods. By creating the more soluble Aminophylline complex, the active substance can be efficiently dissolved and delivered systemically, making it a reliable option for rapid administration when required to address acute airflow obstruction.


General Purpose of Aminophylline

The general purpose of Aminophylline is to promote the relaxation of smooth muscles within the walls of the bronchial airways, thereby directly assisting breathing. This physiological action acts to improve airflow by opposing the factors that cause the airways to narrow.

The main functional result is the dilation or widening of the air passages, which is the primary mechanism by which it relieves reversible airflow obstruction and the related tightening sensation known as bronchospasm. Furthermore, the drug contributes to better respiratory mechanics by exerting a influence on the main muscle of respiration, the diaphragm's contractility.

What side effects are possible with Aminophyline?

Possible Side Effects and Safety Information

The safety profile for aminophylline is characterized by a narrow therapeutic index, meaning there is a small difference between the effective concentration and the concentration at which adverse effects or toxicity may appear. The frequency and severity of reactions are directly linked to the drug's concentration in the bloodstream, with severe reactions becoming more likely when the serum level exceeds 20 mug/mL.

Regulatory documents classify adverse reactions according to the physiological system affected. Commonly reported effects, often listed as incidence not known due to classification methods, include Nausea, Vomiting, Headache, Insomnia, Restlessness, and Tremor. These effects are frequently reported even within the accepted therapeutic range.

Documented Serious Adverse Reactions

The official labeling explicitly documents the risk of serious adverse reactions, which can occur particularly when serum concentrations are too high or if the intravenous formulation is administered too rapidly. These reactions include life-threatening events such as Convulsions/Seizures, Cardiac Arrhythmias, Severe Hypotension, and Cardiac Arrest.

Population-Specific Safety Considerations

The official safety profile highlights increased risk for certain patient populations. Older adults may be more susceptible to serious toxicity due to reduced drug clearance and face a specific risk of Urinary Retention. Pediatric patients, especially infants, require careful monitoring of serum concentration due to highly variable clearance rates. Similarly, patients with Hepatic Impairment exhibit decreased clearance, which increases the overall risk of adverse events.

Overdose and Emergency Response

Overdose and when to seek help

Aminophylline overdose is officially documented to present with distinct symptom clusters affecting the central nervous system (CNS), cardiovascular, and gastrointestinal systems. Initial manifestations may include persistent vomiting, headache, restlessness, and a prominent tremor. Severe toxicity can rapidly escalate to life-threatening outcomes, including seizures (convulsions) and serious ventricular arrhythmias. Laboratory findings associated with toxicity often include hypokalemia and hyperglycemia.

Required Emergency Action

Regulatory documents state that individuals must seek immediate medical attention and contact a regional poison center upon recognizing any signs consistent with an overdose. This requirement is especially urgent for severe symptoms such as irregular heartbeats or seizure activity. The official prescribing information notes that symptoms may have a delayed onset, particularly with prolonged-release formulations, occurring up to twelve hours after overdosage.

Supportive Measures and Monitoring

Management focuses on supportive care, as regulatory information states there is no specific antidote. Officially described procedures include administering multiple-dose activated charcoal to enhance elimination and using intravenous benzodiazepines to control seizures. Continuous electrocardiographic monitoring (ECG) and obtaining serial theophylline concentrations are mandatory monitoring requirements specified in regulatory guidelines. The highest risk of severe complications is noted in the very young and the elderly.

Therapeutic Uses of Aminophyline

What Aminophylline Treats: Main Uses and Benefits

Aminophylline is commonly used to help with conditions characterized by periods of heightened symptoms, specifically those affecting the airways. This medication is generally applied in addressing symptoms related to respiratory discomfort. Its role is relevant for easing symptoms related to heightened physiological activity.

This agent is considered relevant for managing symptoms that interfere with daily comfort across a range of conditions involving episodic or fluctuating manifestations. These conditions often involve inflammatory or irritative processes, and include asthma, chronic bronchitis, and emphysema. In clinical contexts involving acute or unstable symptom patterns, it is used to manage symptoms associated with acute or episodic changes, such as wheezing, shortness of breath, and difficulty breathing.

The patient-oriented benefit is that the treatment contributes to easing the overall symptom burden, and supports the patient during difficult episodes by easing distress. It may help patients cope more steadily with symptom fluctuations. While it may be part of symptomatic management, it may assist with managing but does not cure these chronic conditions.


Quick Fact: Relief for symptoms related to heightened physiological activity (Bronchospasm)

Regulatory References

  1. Aminophylline: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Aminophylline: Official Eligibility and Contraindications

Regulatory agencies define specific population groups and clinical conditions that determine who can and cannot use Aminophylline. This information is based strictly on the official prescribing label and is not a substitute for clinical advice.


Absolute Prohibitions (Contraindications)

Aminophylline is contraindicated and must not be used in patients with a documented hypersensitivity to any xanthine derivative (including theophylline or aminophylline). It is also strictly prohibited in patients with active peptic ulcer disease.

Restricted or Conditional Use

Population/Condition Eligibility Status & Restriction
Infants (<1 year) & Older Adults (>60) Use requires extreme caution and dosage adjustment due to significantly altered drug clearance.
Hepatic Impairment Requires dose reduction and careful monitoring, as liver dysfunction reduces the drug's metabolism.
Congestive Heart Failure Use is restricted and requires careful monitoring and dosage adjustment due to altered clearance.
Pregnancy Use is conditional; requires a careful assessment of risk versus potential benefit.

Eligibility is also restricted for individuals with hyperthyroidism, hypertension, or a history of seizure disorders, necessitating close medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Aminophylline are primarily defined by documented changes in the plasma concentration of its active component, Theophylline, or by synergistic effects.

Regulatory authorities classify combinations with other Xanthine Derivatives (including Theophylline and Pentoxifylline) as contraindicated due to the high documented risk of serious toxicity. Formal restrictions also advise against co-administration with substances like Riociguat.

Pharmacokinetic Interactions

Co-administration with enzyme inhibitors, such as certain Macrolide or Quinolone antibiotics (e.g., Ciprofloxacin, Erythromycin), and substances like Cimetidine, is documented to reduce Theophylline clearance, which formally increases exposure. Conversely, enzyme inducers, including Rifampicin and certain antiepileptics (e.g., Phenytoin), increase clearance, thus decreasing exposure.

Pharmacodynamic and Substance Interactions

Official labeling documents an increased risk of cardiac arrhythmias or hypokalaemia when Aminophylline is co-administered with Sympathomimetics or Beta-2 Agonists, reflecting a synergistic effect. The clearance of Theophylline is also documented to be reduced by conditions like Hepatic Impairment and Acute Febrile Illness. Furthermore, chronic Tobacco Smoking is officially stated to decrease Theophylline exposure through enzyme induction, while the herbal product St. John's Wort is also documented to lower plasma concentrations.

Mechanism of Action

How Aminophylline Works

Aminophylline’s action is defined by a primary dual mechanism focusing on enzyme inhibition and receptor antagonism.

Enzyme Inhibition and Direct Bronchial Relaxation

The drug acts as a non-selective inhibitor of the Phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4. By blocking PDE, the core mechanism prevents the rapid breakdown of intracellular signaling molecules like cAMP. This molecular cascade increases cAMP levels, which ultimately decreases free calcium in the muscle cells, leading directly to a change in the diameter of the bronchial airways (bronchodilation).

Adenosine Receptor Blockade and Anti-Mediator Action

A secondary, yet important, mechanism involves the competitive antagonism of Adenosine receptors throughout the body. Blocking these receptors prevents Adenosine from initiating signaling that promotes bronchoconstriction and the release of pro-inflammatory mediators. This action contributes to the modulation of systems where heightened mediator activity occurs.

Modulation of Diaphragm Contractility and Mechanistic Limitations

The drug's action affects musculoskeletal function by altering calcium dynamics in the diaphragm. This mechanism enhances the contractile force of the diaphragm, leading to an alteration in respiratory mechanical dynamics. However, the anti-inflammatory components of the mechanism, such as HDAC2 restoration and Adenosine antagonism, typically require higher plasma concentrations to significantly engage compared to the primary PDE inhibition.

Dosage and Administration Information

Administration and Official Dosing Principles

Aminophylline administration is split into two primary approaches: Intravenous (IV) for acute, rapid treatment, and Oral (PO) for long-term maintenance. The IV route is reserved for acute exacerbations, while forms such as tablets, extended-release tablets, and solutions are used for chronic control.


Dosing Regimens and Adjustments

All intravenous loading and maintenance doses are calculated based on the patient’s Ideal Body Weight (IBW). A standard IV loading dose is 5.7 mg/kg (aminophylline) and is infused slowly, with the rate not exceeding 25 mg per minute. Maintenance therapy proceeds as a continuous infusion, administered in a two-stage schedule (a higher rate for the initial 12 hours, followed by a lower standard rate). The oral form is typically administered in divided doses every 6 to 12 hours.

Therapeutic Drug Monitoring (TDM) is a standard procedural step to individualize the dose and maintain the serum theophylline concentration within the required therapeutic range (10 to 20 mcg/mL). The maintenance dose is specifically reduced for older adults and patients with liver failure or heart failure due to decreased drug clearance. Conversely, the dose may be increased for patients who smoke, due to enhanced clearance.


Procedural Constraints

For consistent absorption, oral immediate-release tablets and solutions are typically taken with water on an empty stomach. Extended-release tablets are designed to be swallowed whole and not crushed or chewed. A full IV loading dose is not administered if the patient has received any theophylline product within the preceding 24 hours until serum levels are confirmed.

Recent Clinical Evidence

Research evidence / Overview of studies for Aminophylline


Evidence for Use in Acute Asthma Exacerbations

The clinical evaluation of aminophylline, which is often administered intravenously, has focused on research exploring its use when added to existing standard treatment for symptoms of reversible airflow obstruction in acute, severe episodes. Aminophylline was evaluated in numerous short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews to explore its use when added to the current standard of care. These studies monitored functional measures, such as changes in lung capacity, and clinical utilization endpoints, such as the need for hospital admission.

Findings were mixed across the reviewed trials. Some research highlights changes measured in lung function, with certain studies reporting observations of differences in lung capacity measurements compared to control groups. However, the evidence is limited when evaluating major clinical outcomes. Reviews consistently report no significant difference in the likelihood of a patient requiring hospital admission or in the length of time spent in the hospital when aminophylline was added to the standard care protocol.


Evidence for Use in Acute Exacerbations of COPD

Research has also explored the use of intravenous aminophylline as an adjunctive treatment for acute flare-ups of chronic obstructive pulmonary disease (COPD). These studies, often older controlled trials and observational cohorts, were evaluated in hospitalized adults experiencing conditions characterized by fluctuating or episodic manifestations such as acute bronchitis and emphysema.

Research has generally reported inconsistent findings related to major clinical outcomes like the length of hospital stay or other clinical utilization endpoints. The data from these trials are generally sparse, and earlier systematic reviews suggest that initial, short-term research reported inconsistent changes in lung function measures.


What is Still Uncertain About the Research

The research landscape for Aminophylline highlights several areas where certainty remains low or where evidence is limited. Subgroup findings are uncertain, as researchers have not clearly identified which specific patient groups may gain a more consistent benefit from the addition of aminophylline. Additionally, comparative evidence is lacking for its use against newer, more targeted therapies that have become standard in modern practice.

Key Studies & References Aminophylline Injection, USP - U.S. FDA Drug Label Summary (Pfizer)

Frequently Asked Questions (FAQ)

Common questions about Aminophylline (FAQ)


Q: How quickly should someone expect to feel the effects of Aminophylline?

Immediate-release oral forms are rapidly absorbed, with studies indicating that peak concentrations in the bloodstream are often reached within 60 to 90 minutes. The intravenous (IV) route of administration is noted in official documents for its use in acute, rapid treatment. This difference in administration route reflects the need for quick versus chronic management.


Q: Are there any common foods or drinks that should be limited while using Aminophylline?

Official patient information indicates that consuming large quantities of caffeinated foods or beverages may require limitation or avoidance while using this medication. These include items such as coffee, tea, chocolate, and cola drinks. This is because caffeine may increase the central nervous system (CNS) stimulating effects of the medicine, which can heighten the risk of side effects.


Q: Can taking too much caffeine increase the side effects of Aminophylline?

Yes, regulatory warnings indicate that consuming excessive amounts of caffeine from foods, drinks, or other medicines concurrently may lead to increased caffeine-like effects. These common side effects can include nervousness, tremors, nausea, and insomnia. Regulatory documents indicate that excessive stimulation carries a risk of serious adverse effects.


Q: How long does the effect of one dose of Aminophylline usually last?

The duration of the drug's effect varies depending on the specific formulation. For extended-release formulations, the intended release mechanism is structured for administration at intervals such as every 6 to 12 hours. However, official documents emphasize that the exact length of time the medication remains active varies significantly among individuals due to differing rates of drug clearance.


Q: Is Aminophylline known to interact with common pain relievers like ibuprofen?

Official drug labels do not commonly list specific non-prescription pain relievers such as ibuprofen as a direct interaction. However, general warnings are provided regarding specific patient populations. Official warnings note that certain non-steroidal anti-inflammatory drugs (NSAIDs) may worsen the patient's asthma or ulcer conditions. Therefore, caution is noted for use in these patient groups.


Q: Can using Aminophylline affect the results of blood tests?

Aminophylline use requires mandatory Therapeutic Drug Monitoring (TDM), which is a specific blood test to measure the concentration of the active drug in the body. Beyond this specific requirement, official documentation does not typically detail the drug's effects on other routine blood tests.


Q: What type of medical professional typically monitors Aminophylline levels?

Therapeutic Drug Monitoring (TDM) and dose adjustments are procedural steps managed by a patient’s prescribing healthcare provider. This involves coordination between clinical staff and the dispensing pharmacist to ensure the concentration remains within the required therapeutic range.


Q: Can Aminophylline affect kidney function?

Official drug labels note that caution and careful monitoring may be necessary for patients experiencing renal (kidney) dysfunction. The active drug, Theophylline, has been noted in some studies to have diuretic effects. Official labeling notes that caution and careful monitoring may be necessary for patients experiencing renal (kidney) dysfunction, and it is also noted for hepatic (liver) impairment.


Q: Are there specific instructions for what to do if a dose of Aminophylline is missed?

Patient guidance describes a protocol where a missed dose may be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the regulatory guidance suggests skipping the missed dose and returning to the regular dosing schedule. The guidance also advises against taking a double quantity to compensate for the missed dose.


Q: Does Aminophylline have known interactions with over-the-counter cold medicines?

Yes, official interaction warnings exist because many over-the-counter (OTC) cold and sinus medicines contain substances known as Sympathomimetics. Official labeling states that co-administration of Aminophylline with sympathomimetics is associated with an increased risk of adverse cardiovascular effects, such as increased heart rate or a rise in blood pressure.


Q: Is there information on the safety of Aminophylline while breastfeeding?

According to regulatory information, the active drug, Theophylline, is known to pass into human milk. Official sources note that caution is required, as this exposure may be linked to irritability or signs of stimulation in the nursing infant, particularly newborns. Monitoring of the infant for potential side effects is a common procedural note in manufacturer information.


Q: What should be done if a patient experiences a mild side effect, according to official guidance?

Patient guidance describes a protocol where users are instructed to inform their prescribing doctor if common side effects like nausea or headache become severe or persist. For any serious adverse reactions listed, such as convulsions or severe heart rhythm changes, official guidance indicates the need for immediate medical assistance.


Q: Does Aminophylline appear on official lists of high-alert medications?

Yes, the active ingredient in Aminophylline, Theophylline, is frequently included on high-alert medication lists by national safety organizations. This classification is assigned to medications known to carry a heightened risk of causing significant patient harm if errors occur during the administration or use process.

How should Aminophyline be stored and disposed of?

How to Store and Dispose of Aminophylline

Aminophylline must be stored at Controlled Room Temperature, typically defined as between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing. To maintain stability, it must be kept in the original container and stored with the lid tightly closed. Certain liquid formulations may require protection from light and should remain in their outer packaging until use.

All forms of Aminophylline must be stored out of the sight and reach of children.

Unused or expired medication must be disposed of according to local requirements and authorized pharmaceutical waste handling procedures. It should not be disposed of in household trash or poured down a drain unless directed by an official take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aminophyline found in:

A-Z Index: